Diarrhea is one of the most common complications following hematopoietic stem cell
transplantation (HSCT), with an incidence rate of 50%-70%. During HSCT, high-dose
chemotherapy drugs can damage the intestinal mucosa, especially in allogeneic
haploidentical hematopoietic stem cell transplantation, where the pre-treatment dosage is
5-10 times higher than that of conventional chemotherapy. This makes patients prone to
chemotherapy-related diarrhea. Additionally, due to the patients' compromised immune
systems, they are susceptible to other related types of diarrhea. Prolonged diarrhea can
easily lead to damage to the perianal skin and intestinal mucosa, severely affecting the
quality of life while increasing the risk of perianal infections. This, in turn, may
trigger severe systemic infections, sepsis, organ failure, and ultimately transplant
failure. Currently, the main causes of diarrhea are believed to include chemotherapy
toxicity, infections, acute graft-versus-host disease (aGVHD), engraftment syndrome, and
thrombotic microangiopathy. Chemotherapy-related diarrhea is most common in the early
stages of transplantation, with an incidence rate of 78.5%, and a median onset time of -3
days (range: -9 to +10 days). The clinical manifestations of diarrhea are complex, and
the mortality rate is high, with some studies reporting rates as high as 38.7%.
Effectively preventing diarrhea is of great significance for improving patients' quality
of life and prognosis.
In Western medicine, the management of diarrhea primarily focuses on symptom control,
promoting mucosal repair, preventing secondary infections, and maintaining water and
electrolyte balance. While these approaches have achieved certain clinical efficacy, they
still have limitations, particularly in the prevention of diarrhea. Traditional Chinese
medicine (TCM), characterized by its principles of "syndrome differentiation and
treatment" and a "holistic approach," offers greater flexibility. With ongoing research,
the efficacy of TCM in treating diarrhea has gradually become evident. Previous studies
have shown that the mechanisms of TCM in alleviating diarrhea in chemotherapy patients
include: increasing colonic cyclooxygenase-2 and prostaglandin B2 levels, reducing the
movement of water and electrolytes into the intestinal lumen; promoting the production of
serum IL-15, increasing cecal pH, reducing colonic β-glucuronidase activity, and
protecting the structural integrity of the intestinal mucosa; promoting the secretion of
intestinal IgA, increasing the content of vasoactive intestinal peptide, reducing
pro-inflammatory factors such as IL-15, and regulating intestinal immune barrier
function.
Herbal fumigation and external application are important components of TCM external
therapies. Warm liquids can promote blood circulation, working synergistically with
herbal medicine to unblock qi and blood, dredge meridians, and dispel cold and pain. High
concentrations of active drug components act locally on the body, while also avoiding the
metabolic burden on the liver and kidneys associated with oral administration of herbal
medicine. With minimal side effects, these methods are worthy of clinical promotion. This
study aims to explore the clinical application of herbal fumigation and acupoint
application in preventing diarrhea in HSCT patients, with the goal of reducing the
incidence of diarrhea and improving patients' quality of life and prognosis.
If the participant agree to participate in this study, he/she will be randomly assigned
to either the intervention group or the control group, with an equal probability of being
placed in either group. Each group will include 90 participants.
Intervention Group: Starting 24 hours before pre-treatment, the participants will
receive herbal fumigation of the perianal area twice daily (morning and afternoon),
with each session lasting 5 minutes. Additionally, starting 30 minutes after each
meal, acupoint application will be performed on five acupoints: Shenque (CV8),
Tianshu (ST25), and bilateral Zusanli (ST36). The application will last 4 hours per
day.
Control Group: Starting 24 hours before pre-treatment, the participants will receive
povidone-iodine warm water fumigation of the perianal area twice daily (morning and
afternoon), with each session lasting 15 minutes.
After enrollment, the participants will be assigned a unique identification number, and a
medical record will be created for them. During the study,the participants will be
required to cooperate with the research team in implementing the assigned perianal care
measures. The research team will observe and record their daily perianal and local skin
conditions, as well as any occurrences of diarrhea. All interventions will be performed
and monitored by trained professionals.
All information will be managed by the project contact person (Qin Liyuan) and will only
be accessible to members of the research team. It will not be shared with individuals
outside the research team. If any remaining data is to be used for future research after
the study concludes, it will only be used with the participants' consent.
By participating in this study, the participants will receive either herbal fumigation
and acupoint application or standard perianal care, depending on your group assignment.
The research team will closely monitor the participants' health status, aiming to reduce
the incidence of diarrhea and improve prognosis.
